Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
艾吉纳斯(US:AGEN) Businesswire·2025-12-23 13:05LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of clinical results from the ovarian cancer cohort of its Phase 1b C- 800-01 trial evaluating botensilimab plus balstilimab (BOT+BAL) in The Journal for ImmunoTherapy of Cancer (JITC). These results offer a meaningful signal of clinical activity for women with platinum-refractory ovarian cancer...Botensilimab's unique immune activation profile translated into clinically sign ...